+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sarcopenia. Edition No. 2

  • ID: 5178892
  • Book
  • January 2021
  • 384 Pages
  • John Wiley and Sons Ltd
An in-depth examination of sarcopenia’s underexplored yet widespread impact within the field of gerontology

Sarcopenia is common in older men and women, and yet awareness of its clinical relevance is still relatively low. Only formally included in the International Classification of Diseases in 2016, the condition may impact societies with serious health-related and financial consequences unless consistent, effective methods of identification and management are adopted.

This second edition of Sarcopenia provides geriatricians and other healthcare professionals with a revised and expanded examination of this understudied and underdiagnosed condition. Edited by two leading authorities on the subject, it covers the epidemiology and diagnosis of sarcopenia, as well as treatment options and possible prevention strategies. Eight newly written chapters build upon existing knowledge with fresh data on topics including sarcopenia’s biomarkers and its impact on the healthcare economy. This important text:
  • Defines sarcopenia and explains its clinical relevance - Covers all recent scientific evidence - Outlines treatment options - Considers prevention strategies - Discusses sarcopenia as a public health priority - Features eight new chapters covering topics such as sarcopenia’s clinical management, its biomarkers, and its financial impact
Containing vital information for clinicians and other professionals working in geriatric care, nursing homes, nutrition, cancer, endocrinology, surgery, sports medicine and many other specialties, Sarcopenia, second edition, is a groundbreaking and essential new resource.
Note: Product cover images may vary from those shown
Preface

1 Definitions of Sarcopenia

2 Epidemiology of Muscle Mass Loss with Age

3 The Role of Mitochondria in Muscle Function

4 Motor unit remodelling

5 Nutrition, Protein Turnover and Muscle

6 Screening for Sarcopenia

7 Adverse Outcomes and Functional Consequences of Sarcopenia

8 A Lifecourse Approach to Sarcopenia

9 Acute Sarcopenia

10 Sarcopenia, Frailty and Intrinsic Capacity

11 Osteosarcopenia

12 Sarcopenic Obesity

13 Sarcopenia and Cognition

14 Sarcopenia and Other Chronic Organ Diseases

15 Imaging of Skeletal Muscle

16 Measurements of Muscle Mass, Equations and Cut-off Points

17 Deuterated creatine dilution to assess muscle mass (D3Cr muscle mass) in humans: methods, early results and future directions

18 Measurement of Muscle Strength and Power

19 Measurements of Physical Performance

20 Biomarkers for Physical Frailty and Sarcopenia: a “Two-Body Problem”

21 Quality of Life and Sarcopenia

22 Exercise Interventions to Prevent and Improve Sarcopenia

23 Nutritional Approaches to Treat Sarcopenia

24 Beta-hydroxy-beta-methylbutyrate (HMB) and Sarcopenia

25 The Future of Drug Treatments

26 Sarcopenia: Is It Preventable?

27 Financial Impact of Sarcopenia

28 Sarcopenia Management For Clinicians
Note: Product cover images may vary from those shown
John E. Morley Saint Louis University School of Medicine and Saint Louis Veterans' Affairs Medical Center, St. Louis, MO, USA.

Alfonso J. Cruz-Jentoft
Note: Product cover images may vary from those shown
Adroll
adroll